CN117017911B - 一种氢溴酸右美沙芬缓释混悬液及其制备方法 - Google Patents
一种氢溴酸右美沙芬缓释混悬液及其制备方法 Download PDFInfo
- Publication number
- CN117017911B CN117017911B CN202311027102.8A CN202311027102A CN117017911B CN 117017911 B CN117017911 B CN 117017911B CN 202311027102 A CN202311027102 A CN 202311027102A CN 117017911 B CN117017911 B CN 117017911B
- Authority
- CN
- China
- Prior art keywords
- drug
- resin
- dextromethorphan hydrobromide
- suspension
- carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 108
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 title claims abstract description 83
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 title claims abstract description 83
- 238000013268 sustained release Methods 0.000 title claims abstract description 34
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 229920005989 resin Polymers 0.000 claims abstract description 193
- 239000011347 resin Substances 0.000 claims abstract description 193
- 239000011248 coating agent Substances 0.000 claims abstract description 68
- 238000000576 coating method Methods 0.000 claims abstract description 68
- 239000003814 drug Substances 0.000 claims abstract description 63
- 229940079593 drug Drugs 0.000 claims abstract description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 54
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 239000011159 matrix material Substances 0.000 claims abstract description 18
- 238000005470 impregnation Methods 0.000 claims abstract description 15
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims abstract description 15
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 claims abstract description 15
- 230000004584 weight gain Effects 0.000 claims abstract description 12
- 235000019786 weight gain Nutrition 0.000 claims abstract description 12
- 238000011068 loading method Methods 0.000 claims abstract description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- 239000000463 material Substances 0.000 claims description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 238000007599 discharging Methods 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 11
- 229940050929 polyethylene glycol 3350 Drugs 0.000 claims description 10
- 239000001856 Ethyl cellulose Substances 0.000 claims description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 8
- 239000002738 chelating agent Substances 0.000 claims description 8
- 239000003086 colorant Substances 0.000 claims description 8
- 239000006184 cosolvent Substances 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- 229920001249 ethyl cellulose Polymers 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000000375 suspending agent Substances 0.000 claims description 8
- 239000001069 triethyl citrate Substances 0.000 claims description 8
- 235000013769 triethyl citrate Nutrition 0.000 claims description 8
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 6
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 6
- 239000003002 pH adjusting agent Substances 0.000 claims description 6
- 239000003205 fragrance Substances 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 4
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 claims description 3
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 claims description 3
- 235000012730 carminic acid Nutrition 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 229940097275 indigo Drugs 0.000 claims description 3
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- -1 polyoxyethylene Polymers 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000805 composite resin Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 239000008186 active pharmaceutical agent Substances 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 description 42
- 238000009472 formulation Methods 0.000 description 38
- 238000004090 dissolution Methods 0.000 description 26
- 238000000338 in vitro Methods 0.000 description 17
- 238000005406 washing Methods 0.000 description 17
- 239000002994 raw material Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 229940119368 delsym Drugs 0.000 description 10
- STTADZBLEUMJRG-IKNOHUQMSA-N dextromethorphan hydrobromide Chemical compound O.Br.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 STTADZBLEUMJRG-IKNOHUQMSA-N 0.000 description 10
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 9
- 229960001985 dextromethorphan Drugs 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 238000000227 grinding Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 239000000305 astragalus gummifer gum Substances 0.000 description 4
- 238000007598 dipping method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229960003415 propylparaben Drugs 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 235000021433 fructose syrup Nutrition 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ILNSWVUXAPSPEH-USXIJHARSA-N 3-methoxy-morphinan Chemical compound C1CCC[C@H]2[C@H]3CC4=CC=C(OC)C=C4[C@]21CCN3 ILNSWVUXAPSPEH-USXIJHARSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311027102.8A CN117017911B (zh) | 2023-08-15 | 2023-08-15 | 一种氢溴酸右美沙芬缓释混悬液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311027102.8A CN117017911B (zh) | 2023-08-15 | 2023-08-15 | 一种氢溴酸右美沙芬缓释混悬液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117017911A CN117017911A (zh) | 2023-11-10 |
CN117017911B true CN117017911B (zh) | 2024-06-07 |
Family
ID=88633277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311027102.8A Active CN117017911B (zh) | 2023-08-15 | 2023-08-15 | 一种氢溴酸右美沙芬缓释混悬液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117017911B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196436A (en) * | 1990-10-31 | 1993-03-23 | The Procter & Gamble Company | Dextromethorphan antitussive compositions |
US6001392A (en) * | 1996-12-20 | 1999-12-14 | Warner-Lambert Company | Antitussive drugs delivered by ion exchange resins |
CN106963736A (zh) * | 2016-01-14 | 2017-07-21 | 刘宏飞 | 氢溴酸右美沙芬缓释干混悬剂及其制备方法 |
CN109771372A (zh) * | 2019-03-26 | 2019-05-21 | 江苏四环生物制药有限公司 | 一种氢溴酸右美沙芬缓释混悬剂及其制备方法 |
CN116115584A (zh) * | 2022-12-29 | 2023-05-16 | 平光制药股份有限公司 | 一种右美沙芬缓释微丸及混悬液 |
CN116211862A (zh) * | 2023-01-16 | 2023-06-06 | 五邑大学 | 一种盐酸安非他酮/右美沙芬缓控释液体混悬剂及其制备方法与应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130071476A1 (en) * | 2011-08-19 | 2013-03-21 | Subraman Rao Cherukuri | Rapid Melt Controlled Release Taste-Masked Compositions |
US20130115253A1 (en) * | 2011-11-07 | 2013-05-09 | Mahendra R. Patel | Sustained Release Suspension Preparation For Dextromethorphan |
-
2023
- 2023-08-15 CN CN202311027102.8A patent/CN117017911B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196436A (en) * | 1990-10-31 | 1993-03-23 | The Procter & Gamble Company | Dextromethorphan antitussive compositions |
US6001392A (en) * | 1996-12-20 | 1999-12-14 | Warner-Lambert Company | Antitussive drugs delivered by ion exchange resins |
CN106963736A (zh) * | 2016-01-14 | 2017-07-21 | 刘宏飞 | 氢溴酸右美沙芬缓释干混悬剂及其制备方法 |
CN109771372A (zh) * | 2019-03-26 | 2019-05-21 | 江苏四环生物制药有限公司 | 一种氢溴酸右美沙芬缓释混悬剂及其制备方法 |
CN116115584A (zh) * | 2022-12-29 | 2023-05-16 | 平光制药股份有限公司 | 一种右美沙芬缓释微丸及混悬液 |
CN116211862A (zh) * | 2023-01-16 | 2023-06-06 | 五邑大学 | 一种盐酸安非他酮/右美沙芬缓控释液体混悬剂及其制备方法与应用 |
Non-Patent Citations (4)
Title |
---|
Drug release properties of polymer coated ion-exchange resin complexes: experimental and theoretical evaluation;Seong Hoon Jeong et al.;《J Pharm Sci》;20070331;第96卷(第3期);618-632 * |
Fabrication of a novel drug-resin combination device for controlled release of dextromethorphan hydrobromide;Liu et al.;《Colloids Surf B Biointerfaces》;20200130;第189卷;110833 * |
右美沙芬树脂口服缓释混悬液的制备及其释药特性研究;曾环想等;《中国新药杂志》;20070723;第16卷(第14期);1107-1111 * |
含药树脂微囊法制备口服缓释混悬液Ⅰ.右美沙芬口服缓释混悬液;贺芬等;《中国医药工业杂志》;20030620;第34卷(第6期);276-279, 312 * |
Also Published As
Publication number | Publication date |
---|---|
CN117017911A (zh) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU680891C (en) | Controlled release preparation containing a salt of morphine | |
EP1722821B1 (en) | Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same | |
HRP20020111A2 (en) | Pharmaceutical composition containing fenofibrate and preparation method | |
CN1210065C (zh) | 具有改善溶出性能的普仑司特的固体分散体系及其制备方法 | |
US20060121114A1 (en) | Method of manufacturing sustained release microbeads containing venlafaxine HCL | |
CN111514142B (zh) | 含硝羟喹啉前药的药物组合物及其制备方法和应用 | |
US6168806B1 (en) | Orally administrable nifedipine pellet and process for the preparation thereof | |
EP0378137A2 (de) | Neue Arzneiform | |
US8460702B2 (en) | Pharmaceutical compositions | |
CN117017911B (zh) | 一种氢溴酸右美沙芬缓释混悬液及其制备方法 | |
WO2007117110A2 (en) | Sustained-release pellets containing tamsulosin hydrochloride and processes for preparing the same | |
AU2017297117A1 (en) | Oral pharmaceutical preparation having improved content uniformity, containing tamsulosin hydrochloride-containing extended release pellet | |
CZ20014618A3 (cs) | Prostředky tvořené více částicemi s regulovaným uvolňováním selektivního inhibitoru opakované absorpce serotoninu | |
CN113350279B (zh) | 一种盐酸帕罗西汀肠溶缓释混悬剂及其制备方法 | |
CN114209661A (zh) | 呈细粒形式的固体药物组合物 | |
US20040092480A1 (en) | Medicinal composition | |
CN106955276B (zh) | 一种盐酸文拉法辛缓释胶囊组合物 | |
KR101760278B1 (ko) | 에페리손을 유효 성분으로 함유하는 서방성 미립구의 제조방법 | |
KR20210003323A (ko) | 탐수로신 또는 이의 염산염 함유 제약 조성물 및 이의 제조방법 | |
CN113304121B (zh) | 一种盐酸阿比多尔缓释胶囊及其制备方法 | |
CN114159391B (zh) | 重酒石酸卡巴拉汀干混悬剂及其制备方法 | |
CN113750077B (zh) | 一种苯磺酸氨氯地平缓释微丸及其制备方法 | |
CN111407744B (zh) | 一种枸橼酸托法替布长效缓释微球的制备方法 | |
CN110585159B (zh) | 一种含有西罗莫司的片剂 | |
CN116473942A (zh) | 一种氯雷他定缓释胶囊及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: Floor 4, Building D, Biomedical Innovation Park, No. 1, Lutai Avenue, High tech Zone, Zibo City, Shandong Province 255,035 Applicant after: SHANDONG HI-QUAL PHARMATECH CO.,LTD. Applicant after: Shanghai Zezheng Pharmaceutical Technology Co.,Ltd. Address before: Floor 4, Building D, Biomedical Innovation Park, No. 1, Lutai Avenue, High tech Zone, Zibo City, Shandong Province 255,035 Applicant before: SHANDONG HI-QUAL PHARMATECH CO.,LTD. Country or region before: China Applicant before: Zezheng (Shanghai) Biotechnology Co.,Ltd. |
|
GR01 | Patent grant |